Zackrisson Björn, Mercke Claes, Strander Hans, Wennerberg Johan, Cavallin-Ståhl Eva
Department of Oncology, University Hospital, Umeå, Sweden.
Acta Oncol. 2003;42(5-6):443-61. doi: 10.1080/02841860310014886.
A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for head and neck cancer is based on data from 39 randomized trials and 1 meta-analysis. In total, 40 scientific articles are included, involving 20893 patients. The results were compared with those of a similar overview from 1996 including 79 174 patients. The conclusions reached can be summarized as follows: General, non-nasopharynx. Substantial evidence indicates that the tumour effect of radiotherapy can be increased by the concomitant administration of chemotherapeutic agents, particularly cisplatin and 5-fluorouracil. There is moderate evidence of a survival benefit of radiation combined with concomitant chemotherapy compared to radiation alone. However, the results are equivocal. There is substantial evidence in published studies for an increased frequency of severe acute side effects as a result of concomitant chemotherapy and radiotherapy. There are very few studies that allow any estimates of the risk for serious late side effects. There is a weak indication of an increased risk for serious fibrosis.
The general quality of studies and the lack of information on serious side effects indicate a need for large, well-designed clinical studies with a reasonable follow-up. Larynx preservation studies. There is strong evidence that larynx preservation is possible in 50% of the patients surviving for 5 years with hypopharyngeal cancers when treated with neoadjuvant chemotherapy and radical radiotherapy There is a non-significant trend for the overall survival being lower in non-surgically treated patients than in those treated with primary surgery and postoperative radiotherapy Nasopharynx. There is moderate evidence that patients with nasopharyngeal carcinomas of the endemic type benefit from therapy with a combination of chemotherapy and radical radiotherapy. However, the results from the reported studies are equivocal. There is some indication that the acute side effects of radiation are more severe in the concomitant setting than in the neoadjuvant.
There are no data on serious late toxicity. Dose, fractionation schedules. There is some evidence that certain schedules of altered fractionation improve tumour control without increasing severe late side effects. There is some evidence that nervous tissues are more susceptible to damage by altered fractionation. Solid data shows that altered fractionation increases acute side effects. There is moderate evidence that accelerated hyperfractionation may reduce the frequency of serious late side effects while retaining a similar tumour effect as conventional radiotherapy Hypoxic cell sensitizers. Most reported trials reject the usefulness of nitroimidazole derivatives for sensitization of hypoxic tumour cells. There is some evidence that patients with tumours in the pharynx and larynx may benefit from sensitization by nimorazole. Prophylactic treatment of side effects. There is weak evidence that local antibiotics have a clinically significant effect in preventing acute radiotherapy side effects. There is insufficient evidence that radioprotective agents offer clinically significant protection of parotid glands (one study in two publications). There is insufficient evidence that radioprotective agents do not spare tumour tissue. Since the previous report no randomized studies comparing the effectiveness of external beam radiotherapy and brachytherapy have been performed. Both methods are well established and have independently proved to be effective in the treatment of certain head and neck cancers. No conclusion can be drawn regarding their relative effectiveness. Since the previous report no data to guide the use of intraoperative radiotherapy have been identified.
瑞典卫生保健技术评估委员会(SBU)对多种肿瘤类型的放射治疗试验进行了系统评价。科学文献的评估程序另行描述(《肿瘤学学报》2003年;42:357 - 365)。本头颈部癌放射治疗文献综述基于39项随机试验和1项荟萃分析的数据。总共纳入40篇科学文章,涉及20893例患者。将结果与1996年的一项类似综述(涉及79174例患者)的结果进行了比较。得出的结论可总结如下:一般情况,非鼻咽癌。大量证据表明,同时给予化疗药物,特别是顺铂和5 - 氟尿嘧啶,可增强放射治疗的肿瘤效应。有中等证据表明,与单纯放疗相比,放疗联合同步化疗有生存获益。然而,结果并不明确。已发表的研究中有大量证据表明,同步化疗和放疗会增加严重急性副作用的发生率。很少有研究能够对严重晚期副作用的风险进行任何估计。有微弱迹象表明严重纤维化风险增加。
研究的总体质量以及严重副作用信息的缺乏表明,需要进行大规模、设计良好且有合理随访的临床研究。喉保留研究。有强有力的证据表明,对于接受新辅助化疗和根治性放疗的下咽癌患者,50%存活5年的患者有可能保留喉功能。非手术治疗患者的总生存率有低于接受一期手术和术后放疗患者的非显著趋势。鼻咽癌。有中等证据表明,地方性鼻咽癌患者从化疗和根治性放疗联合治疗中获益。然而,报告研究的结果并不明确。有一些迹象表明,同步治疗时放疗的急性副作用比新辅助治疗时更严重。
没有关于严重晚期毒性的数据。剂量、分割方案。有一些证据表明,某些改变分割的方案可改善肿瘤控制,而不增加严重晚期副作用。有一些证据表明,神经组织更容易受到改变分割的损伤。确凿数据表明,改变分割会增加急性副作用。有中等证据表明,加速超分割可能降低严重晚期副作用的发生率,同时保持与传统放疗相似的肿瘤效应。乏氧细胞增敏剂。大多数报告的试验否定了硝基咪唑衍生物对乏氧肿瘤细胞增敏的作用。有一些证据表明,咽喉部肿瘤患者可能从尼莫唑增敏中获益。副作用的预防性治疗。有微弱证据表明,局部使用抗生素在预防急性放疗副作用方面有临床显著效果。没有足够证据表明放射防护剂对腮腺有临床显著的保护作用(两篇出版物中的一项研究)。没有足够证据表明放射防护剂不会使肿瘤组织免受影响。自上次报告以来,未进行比较外照射放疗和近距离放疗有效性的随机研究。两种方法都已确立,并且已独立证明在某些头颈部癌的治疗中有效。关于它们的相对有效性无法得出结论。自上次报告以来,未发现指导术中放疗使用的数据。